Singlomics Beijing DanXu Biopharmaceuticals Co., Ltd.
- Biotech or pharma, therapeutic R&D
Singlomics Biopharmaceuticals is an innovative biopharmaceutical company committed to the discovery and development of antibody therapeutics for oncology, inflammation and autoimmune diseases using single-cell sequencing technology. Singlomics has built an integrated antibody development platform from antigen immunization, single B cell antibody discovery, DMS antibody screening to AI antibody engineering, which can achieve high-quality, high-throughput and high-efficiency rapid discovery of antibody drugs. Singlomics has completed series B round of financing from investors in the medical and health field to develop innovative biological therapeutics for highly unmet clinical needs.
Singlomics is seeking strategic partners to license or co-develop its cutting-edge oncology, Inflammation and Immunology assets:
- DXP-106: IL-1RAP mAb
- DXP-006: IL-1RAP mAb
- DXP-102: TREM-1 mAb
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}